RXRA Knockout Cell Line (A549)

The choice depends on whether you are studying RXRA's role as the dominant retinoid X receptor in most tissues or its specific contributions distinct from RXRB and RXRG. The Knockout line is appropriate for asking whether RXRA is required for nuclear receptor signaling — RXRA is the most broadly expressed RXR paralog and the principal heterodimerization partner for RAR, PPAR, LXR, FXR, VDR, TR, and other partner receptors in most cellular contexts. Overexpression is useful for studying RXRA gain-of-function or for testing rexinoid pharmacology. Important consideration: RXRA, RXRB, and RXRG have substantial functional overlap as heterodimer partners. Single RXRA knockout in A-549 may show partial phenotypes if RXRB compensates — RXRG is typically less expressed in non-hematopoietic and non-neural tissues. For lung cancer nuclear receptor research, the EDITGENE RXRA Knockout in A-549 is informative for studies focused on RXRA-specific contributions to lung cancer biology and retinoid signaling. This product complements the parallel RXRB Knockout in HAP1 and the RXRA & RXRB Double Knockout in A-549; the single RXRA knockout in A-549 enables direct paralog-specific functional comparisons within the same lung cancer background. Rescue with wild-type or DNA-binding/ligand-binding-deficient RXRA enables structure-function studies.

Primary applications: • RXRA-specific transcriptional dependencies: identification of nuclear receptor partner-driven gene programs uniquely dependent on RXRA versus RXRB through comparative analyses with the parallel RXRB Knockout in HAP1. • Lung cancer biology: retinoid-induced differentiation, proliferation, and EMT phenotypes given RAR-RXRA signaling's documented role in lung cancer biology and chemoprevention research. • Bexarotene/rexinoid response: critical genetic control for testing RXR-targeted compounds in lung cancer contexts — bexarotene (Targretin) and emerging RXR-selective agonists are being investigated for NSCLC. • Paralog dissection comparison: side-by-side comparison with RXRA & RXRB Double Knockout in A-549 (also available) reveals which phenotypes require both paralogs versus RXRA alone. EDITGENE recommends this model for researchers investigating RXRA-specific nuclear receptor signaling, lung cancer retinoid biology, and rexinoid pharmacology in a defined lung cancer background.

Yes. RXRA rescue experiments require attention to multi-domain nuclear receptor architecture and paralog considerations: • Construct design: use a codon-modified RXRA sequence with a small C-terminal tag (FLAG, HA). RXRA has the canonical nuclear receptor architecture (N-terminal A/B with AF-1, DNA-binding C domain, hinge D, ligand-binding E domain with AF-2) — preserve all elements. • DNA-binding-deficient rescue: zinc finger DBD mutations (e.g., conserved C-to-S substitutions) abolish DR-element binding and serve as the standard specificity control for transcription-dependent functions. • Ligand-binding-deficient rescue: LBD mutations affecting 9-cis-retinoic acid or rexinoid binding enable distinguishing ligand-dependent from constitutive activities — useful for separating bexarotene-induced effects from baseline RXRA function. • Paralog considerations: RXRB expression status in rescue cells aids interpretation given functional redundancy. For comprehensive paralog dissection, single-RXRA rescue in the RXRA & RXRB Double Knockout (also available in A-549) provides cleaner readouts than rescue in this single-RXRA knockout. • Functional readout: rescue should restore RAR-RXR retinoid signaling (DR5 reporter), PPAR-RXR lipid metabolism signaling (DR1 reporter), and target gene expression in lung cancer-relevant contexts. A-549 transduces efficiently with lentivirus and supports stable rescue line generation in the same lung cancer background as the RXRB and double-knockout products, enabling rigorous comparative analysis across the three-line series.